Simcere Pharmaceutical Group Ltd
HKEX:2096
Income Statement
Earnings Waterfall
Simcere Pharmaceutical Group Ltd
Revenue
|
6.6B
CNY
|
Cost of Revenue
|
-1.6B
CNY
|
Gross Profit
|
5B
CNY
|
Operating Expenses
|
-4.3B
CNY
|
Operating Income
|
697.6m
CNY
|
Other Expenses
|
17.2m
CNY
|
Net Income
|
714.8m
CNY
|
Income Statement
Simcere Pharmaceutical Group Ltd
Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|
Revenue | ||||||||
Revenue |
4 509
N/A
|
4 703
+4%
|
5 000
+6%
|
5 579
+12%
|
6 324
+13%
|
7 004
+11%
|
6 608
-6%
|
|
Gross Profit | ||||||||
Cost of Revenue |
(900)
|
(969)
|
(1 080)
|
(1 180)
|
(1 327)
|
(1 588)
|
(1 624)
|
|
Gross Profit |
3 609
N/A
|
3 735
+3%
|
3 920
+5%
|
4 399
+12%
|
4 997
+14%
|
5 416
+8%
|
4 984
-8%
|
|
Operating Income | ||||||||
Operating Expenses |
(3 110)
|
(3 474)
|
(3 686)
|
(3 851)
|
(4 239)
|
(4 671)
|
(4 287)
|
|
Selling, General & Administrative |
(1 982)
|
(2 193)
|
(2 419)
|
(2 584)
|
(2 835)
|
(3 140)
|
(2 855)
|
|
Research & Development |
(1 142)
|
(1 315)
|
(1 417)
|
(1 441)
|
(1 728)
|
(1 853)
|
(1 563)
|
|
Other Operating Expenses |
14
|
34
|
150
|
174
|
325
|
322
|
131
|
|
Operating Income |
499
N/A
|
261
-48%
|
233
-10%
|
548
+135%
|
758
+38%
|
745
-2%
|
698
-6%
|
|
Pre-Tax Income | ||||||||
Interest Income Expense |
306
|
330
|
766
|
382
|
139
|
1 634
|
(717)
|
|
Non-Reccuring Items |
(0)
|
512
|
402
|
2
|
(11)
|
780
|
759
|
|
Pre-Tax Income |
805
N/A
|
1 102
+37%
|
1 402
+27%
|
932
-33%
|
886
-5%
|
3 159
+256%
|
740
-77%
|
|
Net Income | ||||||||
Tax Provision |
(141)
|
(68)
|
97
|
73
|
40
|
(20)
|
(26)
|
|
Income from Continuing Operations |
664
|
1 034
|
1 499
|
1 006
|
927
|
3 139
|
714
|
|
Income to Minority Interest |
5
|
7
|
8
|
7
|
4
|
3
|
1
|
|
Net Income (Common) |
670
N/A
|
1 042
+56%
|
1 507
+45%
|
1 013
-33%
|
931
-8%
|
3 142
+238%
|
715
-77%
|
|
EPS (Diluted) |
0.28
N/A
|
0.41
+46%
|
0.58
+41%
|
0.39
-33%
|
0.36
-8%
|
1.2
+233%
|
0.27
-78%
|